Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$3.61
-3.5%
$2.55
$1.89
$4.09
$1.12B0.363.34 million shs6.19 million shs
Annexon, Inc. stock logo
ANNX
Annexon
$2.41
-1.6%
$2.11
$1.29
$7.85
$268.80M1.261.47 million shs1.14 million shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$20.68
-3.9%
$19.24
$13.30
$30.03
$1.06B0.79299,814 shs1.44 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$25.66
+2.1%
$22.45
$16.16
$26.55
$1.02B0.74211,804 shs741,649 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-3.48%+5.87%+76.96%+56.28%+29.39%
Annexon, Inc. stock logo
ANNX
Annexon
-1.63%+1.26%+18.72%+7.11%-48.17%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-3.90%-2.91%+28.69%-1.85%-2.36%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+2.15%+7.45%+4.73%+19.57%+46.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.3305 of 5 stars
3.41.00.00.03.13.30.0
Annexon, Inc. stock logo
ANNX
Annexon
2.2392 of 5 stars
3.52.00.00.02.70.80.6
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.4904 of 5 stars
3.51.00.00.02.54.20.0
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
3.5056 of 5 stars
0.82.02.51.12.53.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.75
Moderate Buy$8.33130.84% Upside
Annexon, Inc. stock logo
ANNX
Annexon
3.00
Buy$12.50418.67% Upside
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00
Buy$39.6091.49% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.67
Reduce$21.80-15.04% Downside

Current Analyst Ratings Breakdown

Latest ANNX, ELVN, ABCL, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$21.00 ➝ $26.00
6/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.00
6/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$37.00
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas Exane
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Neutral$24.00
5/16/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $10.00
5/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$36.00 ➝ $27.00
5/15/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$39.00 ➝ $40.00
5/14/2025
Annexon, Inc. stock logo
ANNX
Annexon
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $14.00
5/13/2025
Annexon, Inc. stock logo
ANNX
Annexon
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $11.00
5/8/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $21.00
(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$28.83M37.37N/AN/A$3.58 per share1.01
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/A$2.75 per shareN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$6.34 per shareN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B1.02$2.16 per share11.88$6.34 per share4.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$162.86M-$0.56N/AN/AN/A-737.56%-15.98%-12.38%8/5/2025 (Estimated)
Annexon, Inc. stock logo
ANNX
Annexon
-$138.20M-$1.18N/AN/AN/AN/A-54.45%-46.56%8/11/2025 (Estimated)
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7832.9012.220.472.68%30.51%6.89%8/27/2025 (Estimated)

Latest ANNX, ELVN, ABCL, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.51-$0.57-$0.06-$0.57N/AN/A
5/12/2025Q1 2025
Annexon, Inc. stock logo
ANNX
Annexon
-$0.30-$0.37-$0.07-$0.37N/AN/A
5/8/2025Q1 2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.87%N/A61.54%N/A

Latest ANNX, ELVN, ABCL, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
10.15
10.15
Annexon, Inc. stock logo
ANNX
Annexon
N/A
7.99
7.99
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
21.07
21.06
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Annexon, Inc. stock logo
ANNX
Annexon
N/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.90%
Annexon, Inc. stock logo
ANNX
Annexon
11.87%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
25.90%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
500298.42 million212.18 millionOptionable
Annexon, Inc. stock logo
ANNX
Annexon
60109.71 million96.69 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5049.07 million36.36 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable

Recent News About These Companies

Phibro Animal Health (NASDAQ:PAHC) PT Set at $26.00 by Morgan Stanley
Best Growth Stocks to Buy for June 25th
Phibro Animal Health Corporation (PAHC) - Yahoo Finance
Q1 EPS Forecast for Phibro Animal Health Raised by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$3.61 -0.13 (-3.48%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$3.60 -0.01 (-0.42%)
As of 06/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Annexon stock logo

Annexon NASDAQ:ANNX

$2.41 -0.04 (-1.63%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$2.48 +0.07 (+2.90%)
As of 06/27/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$20.68 -0.84 (-3.90%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$20.68 0.00 (0.00%)
As of 06/27/2025 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$25.66 +0.54 (+2.15%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$25.66 0.00 (0.00%)
As of 06/27/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.